List of Excipients in Branded Drug BENZNIDAZOLE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Exeltis USA Inc	BENZNIDAZOLE	benznidazole	0642-7463	CELLULOSE, MICROCRYSTALLINE
Exeltis USA Inc	BENZNIDAZOLE	benznidazole	0642-7463	CROSCARMELLOSE SODIUM
Exeltis USA Inc	BENZNIDAZOLE	benznidazole	0642-7463	LACTOSE MONOHYDRATE
Exeltis USA Inc	BENZNIDAZOLE	benznidazole	0642-7463	MAGNESIUM STEARATE
Exeltis USA Inc	BENZNIDAZOLE	benznidazole	0642-7463	STARCH, CORN
Exeltis USA Inc	BENZNIDAZOLE	benznidazole	0642-7464	CELLULOSE, MICROCRYSTALLINE
Exeltis USA Inc	BENZNIDAZOLE	benznidazole	0642-7464	CROSCARMELLOSE SODIUM

Benznidazole Excipient Strategy and Commercial Opportunities

Last updated: September 26, 2026

Benznidazole has a differentiated formulation opportunity in pediatric Chagas disease. The strongest commercial prospects are dispersible tablets, taste-masked oral liquids, flexible-dose multiparticulates, and regionally manufacturable products for public-health procurement. The core formulation challenge is not discovery of a new active ingredient. It is delivering accurate, acceptable, stable doses to infants and children who require weight-based treatment and may have difficulty swallowing conventional tablets.

Benznidazole is approved in the United States as Lampit tablets for treatment of Chagas disease caused by Trypanosoma cruzi in pediatric patients from birth to younger than 12 years who weigh at least 2.5 kg. The FDA-approved strengths are 12.5 mg and 50 mg tablets for oral suspension.[1] The product has orphan-drug positioning, but its addressable market is concentrated in Latin America, the United States, Spain, and other countries with diagnosed Chagas populations.

What excipient strategy is best for benznidazole?

The strongest platform is a rapidly dispersible, taste-masked tablet that can be administered as a liquid or swallowed whole when appropriate.

Benznidazole products need to address five formulation requirements:

1. Accurate weight-based dosing.
2. Rapid dispersion in a small volume of water.
3. Reduced bitterness and chemical aftertaste.
4. Low-dose content uniformity for infants.
5. Stability under hot, humid distribution conditions.

A tablet for oral suspension is commercially attractive because it avoids the transport and stability burden of a ready-to-use liquid. It also supports dose adjustment by administering partial tablet quantities or by dispersing a known tablet dose in a measured volume.

Recommended excipient functions

Formulation function	Candidate excipient classes	Commercial purpose
Diluent	Microcrystalline cellulose, lactose, mannitol	Tablet mass, compressibility, mouthfeel
Superdisintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Rapid dispersion in water
Binder	Povidone, low-substituted hydroxypropyl cellulose	Mechanical strength
Lubricant	Magnesium stearate, sodium stearyl fumarate	Manufacturing efficiency
Wetting agent	Sodium lauryl sulfate, poloxamers	Improved wetting and dispersion
Taste masking	Ion-exchange resins, polymer coatings, lipid barriers, cyclodextrins	Lower bitterness
Suspending agent for liquid products	Xanthan gum, sodium carboxymethylcellulose, hydroxypropyl cellulose	Dose uniformity after reconstitution
Sweetener	Sucralose, saccharin sodium, acesulfame potassium, sucrose	Palatability
Flavor	Fruit, vanilla, or neutral pediatric flavors	Patient acceptance
Buffer	Citrate or phosphate systems	pH control and stability
Antioxidant or chelator	Product-specific, subject to compatibility testing	Protection against degradation

The excipient choice should prioritize compendial status, pediatric acceptability, global availability, and compatibility with direct compression or dry granulation. A formulation that depends on a specialized excipient with limited Latin American supply may have lower procurement value even if it performs well in laboratory testing.

What are the main formulation problems with benznidazole?

Benznidazole is a small nitroimidazole derivative with limited aqueous solubility and an intensely bitter taste. Pediatric administration is therefore the primary product-development constraint.

Dose flexibility

Treatment is weight based. A commercial product must accommodate changing doses as children grow and must support different treatment protocols across national programs. A single 50 mg tablet is poorly suited to infants. The 12.5 mg strength improves flexibility, but a broader platform could include:

• 6.25 mg mini-tablets;
• 12.5 mg dispersible tablets;
• 25 mg and 50 mg tablets;
• multiparticulate sachets;
• granules for oral suspension;
• concentrated oral liquid for hospital or specialist use.

Mini-tablets can improve dose precision, but they require stronger manufacturing controls for content uniformity and may increase packaging complexity.

Taste masking

Benznidazole's bitterness can cause refusal, spitting, incomplete dosing, and poor adherence. Taste masking is likely the most defensible technical differentiator for a new product.

Potential approaches include:

• polymer-coated particles;
• ion-exchange resin complexes;
• lipid or wax-coated drug particles;
• drug-loaded microparticles;
• cyclodextrin complexes;
• orally disintegrating matrices with sweetener and flavor systems.

Taste masking must be tested after dispersion, not only in the intact dosage form. A tablet that is acceptable when swallowed may be unacceptable when suspended in water. The taste profile also changes with residence time in the mouth.

Dispersion and sedimentation

A dispersible tablet should disintegrate rapidly in a small volume of water without forming large agglomerates. A suspension product must maintain dose uniformity between the first and last administered portions.

Crospovidone can provide rapid tablet breakup. A wetting agent may reduce floating or clumping of hydrophobic particles. For a ready-to-use or reconstituted liquid, the viscosity must balance sedimentation control against ease of pouring and swallowing.

Stability in tropical markets

Chagas disease is concentrated in countries where storage conditions may include high temperature and humidity. Moisture-sensitive excipients, hygroscopic powders, and liquid formulations may increase the risk of degradation or microbial growth.

Blister packaging with a high moisture barrier is generally more robust than multidose bottles. Unit-dose sachets can improve portability and dose control but may raise packaging costs. A dry dispersible tablet is likely to have a lower total supply-chain risk than a multidose aqueous suspension.

What formulations are protected by the existing Lampit product?

Lampit is FDA-approved as 12.5 mg and 50 mg tablets for oral suspension. FDA labeling identifies inactive ingredients including conventional tableting and disintegration excipients such as microcrystalline cellulose, crospovidone, magnesium stearate, povidone, and sodium lauryl sulfate, with composition depending on the approved presentation.[1]

The product demonstrates that a tablet-for-suspension model is acceptable to the FDA. It does not eliminate opportunities for differentiated products. Potential improvements include:

• stronger taste masking;
• smaller unit doses;
• easier dispersion;
• reduced residue after preparation;
• higher humidity stability;
• single-dose packaging;
• lower-cost excipient systems;
• improved compatibility with local manufacturing.

A competing product should avoid relying on an identical excipient architecture unless the formulation is independently developed and freedom-to-operate analysis confirms that no live formulation rights apply.

What is the FDA regulatory status of benznidazole?

FDA approved Lampit under NDA 209570 on August 29, 2017, for pediatric patients with Chagas disease.[1] The approval gave the product a US regulatory foothold in a neglected tropical disease with limited treatment alternatives.

Regulatory item	Status
Active ingredient	Benznidazole
Brand	Lampit
US sponsor	Exeltis USA, Inc. is identified in current product materials
NDA	209570
FDA approval	August 29, 2017
Dosage forms	12.5 mg and 50 mg tablets for oral suspension
Indication	Pediatric Chagas disease caused by T. cruzi
Patient population	Birth to younger than 12 years; weight at least 2.5 kg
Regulatory category	Orphan-disease product
Primary differentiation	Pediatric tablet-for-suspension delivery

A follow-on product would need to assess the applicable FDA pathway, including an abbreviated application if the reference product and dosage form support that route. The regulatory strategy will depend on whether the product is an equivalent tablet, a new oral suspension, a mini-tablet, or another dosage form.

When does benznidazole lose exclusivity?

Benznidazole's original active-ingredient patent protection is not the principal commercial barrier in the United States. The relevant questions are current FDA exclusivity, Orange Book patent listings, regulatory pathway, and market procurement access.

FDA orphan-drug exclusivity generally runs for seven years from approval for the protected indication under Section 527 of the Federal Food, Drug, and Cosmetic Act.[2] Because Lampit was approved in 2017, its initial orphan exclusivity period would ordinarily have ended in 2024, subject to the precise designation, indication, and regulatory record.

A product-specific analysis should distinguish:

• active-ingredient patent expiry;
• formulation patent expiry;
• method-of-use patent expiry;
• orphan-drug exclusivity;
• pediatric exclusivity;
• regulatory exclusivity for any later-approved indication;
• patent listings in the FDA Orange Book.

The commercial opportunity is therefore more likely to depend on formulation differentiation, manufacturing economics, and procurement contracts than on a long remaining period of brand exclusivity.

What is the Orange Book status of benznidazole?

The Orange Book is the controlling source for current listed patents and exclusivity associated with an approved reference product.[3] For benznidazole, the business risk is unlikely to be defined solely by a compound patent. Any active listings would more likely concern dosage form, formulation, or method of use.

A generic sponsor should evaluate:

• whether the reference product has active patent listings;
• whether a Paragraph IV certification is required;
• whether listed claims cover the tablet-for-suspension technology;
• whether the proposed product uses a materially different excipient system;
• whether the proposed indication overlaps the listed method-of-use claims.

A Paragraph IV challenge could create a litigation pathway if a listed patent remains active. If no blocking patent is listed, the launch timing would be driven more by FDA review, development data, and procurement qualification.

Which companies are challenging benznidazole exclusivity?

No major public Paragraph IV challenge or settlement involving Lampit is established in the core FDA materials cited here. The competitive field is more fragmented than the market for high-revenue small-molecule products.

Potential competitors include:

• generic-drug manufacturers developing equivalent tablets;
• Latin American manufacturers supplying benznidazole;
• nonprofit or public-health organizations supporting access products;
• contract manufacturers producing dispersible or pediatric dosage forms;
• pharmaceutical companies developing alternative Chagas treatments.

Because Chagas treatment procurement often involves governments, nonprofit organizations, and international agencies, a technically superior product may compete through tenders rather than conventional retail pharmacy channels.

How strong is the benznidazole patent estate?

The estate is strongest around product execution rather than the old active ingredient. New patentable subject matter could include:

• defined taste-masked benznidazole particles;
• specific excipient ratios;
• rapidly dispersible tablets;
• mini-tablet arrays;
• stable reconstituted suspensions;
• moisture-resistant packaging combinations;
• multiparticulate systems;
• manufacturing processes that improve content uniformity or dissolution.

Patent strength depends on claim breadth and reproducibility. A narrow claim directed to one sweetener, one polymer, or one particle-size range may be easy to design around. A stronger estate would combine composition, performance, and manufacturing claims, such as rapid dispersion, controlled particle size, acceptable taste, and defined stability after storage.

Trade-secret protection may be important for coating parameters, granulation conditions, flavor masking, and scale-up controls. These process details may be difficult to infer from the finished product.

What are the commercial opportunities for benznidazole excipients?

The highest-value opportunities are likely to be platform products rather than individual excipients.

Pediatric dispersible tablets

A 6.25 mg or 12.5 mg tablet with validated taste masking could improve dosing for infants and small children. The product could compete on reduced dosing error and better adherence.

Ready-to-use oral suspension

A liquid may be preferred for very young children, but it carries higher microbial, preservative, shipping, and stability burdens. A preservative-free, unit-dose suspension could command value in hospital and specialist settings if its shelf life is adequate.

Dry granules or sachets

Single-dose sachets can support rural distribution and reduce contamination risk. They also allow a manufacturer to separate the drug from the reconstitution vehicle until use.

Excipient systems

Suppliers can commercialize prematched systems combining:

• a taste-masking carrier;
• a rapidly dispersible tablet base;
• a pediatric sweetener and flavor system;
• a humidity-protective packaging format.

Such systems can shorten development time for regional manufacturers and support technology-transfer agreements.

Contract manufacturing and licensing

A developer with a validated pediatric formulation could license the product to manufacturers in Brazil, Argentina, Bolivia, Mexico, Spain, and other countries with established Chagas treatment programs. A regional licensing model may be more suitable than a single global commercialization strategy because registration, procurement, and manufacturing requirements differ by jurisdiction.

How does benznidazole compare with nifurtimox?

Benznidazole and nifurtimox are the principal approved drugs used for Chagas disease, but their formulation opportunities differ.

Factor	Benznidazole	Nifurtimox
Main pediatric opportunity	Dispersible tablets, mini-tablets, taste masking	Pediatric tablets and flexible dosing
US pediatric approval	Lampit approved for children from birth to younger than 12 years	Lampit-like benznidazole approval history differs from nifurtimox products
Core formulation issue	Bitter taste, limited solubility, dose flexibility	Tolerability, dosing complexity, pediatric administration
Commercial differentiator	Rapid dispersion and acceptable taste	Adherence support and dose flexibility
Procurement market	Chagas-focused public-health programs	Chagas-focused public-health programs

A formulation company should not assume that an excipient platform optimized for benznidazole will transfer directly to nifurtimox. Solubility, degradation, taste, and dose requirements must be evaluated separately.

What generic launch risks exist for benznidazole?

The principal launch risks are:

1. Limited diagnosed patient volume in high-income markets.
2. Dependence on public procurement and tender cycles.
3. Pediatric bioavailability and dose-uniformity requirements.
4. Taste-masking performance after dispersion.
5. Tropical stability and packaging costs.
6. Country-specific registration requirements.
7. Limited commercial return on conventional tablet development.
8. Potential manufacturing variability in low-dose strengths.

A generic tablet identical in function to Lampit may face price competition. A differentiated product can defend value through better dosing, lower wastage, improved adherence, reduced storage burden, or procurement advantages.

Key Takeaways

• Benznidazole's strongest formulation opportunity is a taste-masked, rapidly dispersible pediatric tablet.
• A 6.25 mg or 12.5 mg mini-tablet could improve weight-based dosing for young children.
• Dry dosage forms are generally more attractive than ready-to-use liquids for tropical distribution.
• Excipients should be selected for taste masking, rapid dispersion, moisture stability, pediatric acceptability, and global supply.
• Lampit was FDA-approved in 2017 under NDA 209570 in 12.5 mg and 50 mg tablet-for-suspension presentations.
• Initial orphan-drug exclusivity associated with the 2017 approval would ordinarily have ended in 2024.
• The main competitive barrier is likely regulatory execution and procurement access rather than a long-lived compound patent.
• The most defensible new IP would combine formulation composition, measurable performance, and manufacturing-process claims.
• Commercial success is more likely through public-health tenders, regional licensing, and contract manufacturing than through a conventional US retail launch.

FAQs About Benznidazole Excipient and Commercial Strategy

Can benznidazole be formulated as an orally disintegrating tablet?

Yes. An orally disintegrating or rapidly dispersible tablet is technically feasible, but taste masking is essential because drug particles can remain in the mouth after tablet breakup.

Which excipient is best for benznidazole taste masking?

No single excipient is universally optimal. Polymer-coated particles, ion-exchange resins, lipid barriers, and cyclodextrin systems should be compared using sensory testing after dispersion.

Is a benznidazole oral suspension commercially attractive?

It can be attractive for infants, hospitals, and specialist clinics. Its disadvantages are higher microbial risk, shorter stability, heavier shipping, and greater packaging complexity than a dry dispersible tablet.

Are benznidazole formulation patents commercially important?

They can be. Claims covering taste masking, rapid dispersion, stability, particle engineering, or dose-flexible delivery may create meaningful differentiation even when compound patent protection has expired.

What is the best market-entry strategy for a new benznidazole product?

A regional strategy focused on pediatric dispersible tablets, public-health procurement, and local manufacturing partnerships is more commercially credible than relying only on US retail sales.

References

1. U.S. Food and Drug Administration. (2017). Lampit (benznidazole) tablets for oral suspension, prescribing information. FDA.

2. U.S. Food and Drug Administration. (2023). Orphan drug designation and exclusivity. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. World Health Organization. (2023). Chagas disease (American trypanosomiasis). WHO.

5. Drugs for Neglected Diseases initiative. (2011). New pediatric dosage form of benznidazole for Chagas disease. DNDi.